Information Provided By:
Fly News Breaks for January 20, 2016
CLVS
Jan 20, 2016 | 16:20 EDT
Credit Suisse analyst Kennen MacKay started Clovis Oncology with an Outperform rating and $32 price target. The stock is oversold given the potential for near-term approval of rociletinib, MacKay tells investors in a research note initiating coverage of the smid-cap biotechnology sector.
News For CLVS From the Last 2 Days
There are no results for your query CLVS